News
The company will use the funds to develop new products, expand its operations and acquire other companies.
The funding boosts the Australia-based company's valuation to $465 million and brings its total raise to almost $100 million.
The company will use the funds to develop AI capabilities and move into weight loss, cardiometabolic care, diabetes, thyroid disorders and cardiovascular disease.
The company said it worked with mental health and teen experts to help chatGPT recognize signs that a teen may be thinking of harming themselves.
The study aims to help people with speech and mobility challenges use the companies' technologies to interact using brain signals, eye gaze or head pose.
Also, JLK has received its seventh regulatory clearance from Japan for its stroke AI.
The company was sold to an affiliate of New Enterprise Associates and a consortium of investors for $1.465 billion and ceased trading on the NYSE on Oct. 2.
The company's platform predicts how people in a clinical trial will respond to treatment.
The launch comes a day after General Catalyst CEO Hemant Taneja announced the closing of the firm’s $485 million acquisition of Ohio healthcare system Summa Health.
The OLED contact lens-based ERG test could be the first of its kind in the world.